<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696042</url>
  </required_header>
  <id_info>
    <org_study_id>AIM-NETs</org_study_id>
    <nct_id>NCT04696042</nct_id>
  </id_info>
  <brief_title>Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs</brief_title>
  <acronym>AIM-NETs</acronym>
  <official_title>Prospective Observational Study to Assess the Effectiveness and Safety of Lanreotide Autogel® in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Asia Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lanreotide Autogel® has been established as a standard of care for patients with locally&#xD;
      advanced or metastatic GEP-NETs based on the success of CLARINET trial. However, only few&#xD;
      patients with Asian ethnicity were included in the trial.&#xD;
&#xD;
      According to the nationwide comprehensive study of patients with GEP-NET in Korea, hindgut&#xD;
      primary NETs(Rectal) occured more frequently than western countries. However, small intestine&#xD;
      or lung primary NET is relatively rare compared with western countries.1) Considering the&#xD;
      clinical characteristics of GEP-NETs are distinct between the patients in Asian and Western&#xD;
      countries, further evaluation on the efficacy and safety of Lanreotide Autogel® in Asian&#xD;
      patients with GEP-NETs is needed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Progression-free survival rate at 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients without tumor progression defined by RECIST version 1.1 at 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time between lanreotide treatment initiation and disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients with tumor response by RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rates</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients with tumor response and stable disease by RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time between lanreotide treatment initiation and death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chromogranin A response</measure>
    <time_frame>2 years</time_frame>
    <description>Change of serum chromogranin A levels during lanreotide treatment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Lanreotide</arm_group_label>
    <description>Patients treated with lanreotide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide autogel</intervention_name>
    <description>Lanreotide autogel 90-120 mcg, every 4 weeks</description>
    <arm_group_label>Lanreotide</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        G1-2 GEP-NET patients who would be treated with lanreotide will be included in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Male or female subject aged ≥18 years and legally capable to provide informed consent&#xD;
&#xD;
          -  Functioning or non-functioning gastroenteropancreatic (GEP)-neuroendocrine tumor (NET)&#xD;
             or unknown primary-NET&#xD;
&#xD;
          -  Well differentiated tumor&#xD;
&#xD;
          -  Grade (G) 1, G2 according to the 2017 World Health Organization (WHO) criteria&#xD;
&#xD;
          -  Subject already treated with Lanreotide Autogel® for the period up to 5 months,&#xD;
             according to local standard of care, prior to documentation into this study&#xD;
&#xD;
          -  Use of Lanreotide autogel® monotherapy by local label (SmPC).&#xD;
&#xD;
          -  Concomitant locoregional therapy such as surgery, RFA or TAE is allowed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Parallel participation in an interventional study&#xD;
&#xD;
          -  Lanreotide treatment for more than 5 months prior inclusion into the study&#xD;
&#xD;
          -  Prior anti-proliferative medication with somatostatin analogue (e.g. Octreotide LAR).&#xD;
&#xD;
          -  Concomitant anti-proliferative systemic medication/therapies for GEP-NET are not&#xD;
             allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changhoon Yoo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changhoon Yoo</last_name>
    <phone>+821099006798</phone>
    <email>cyoo.amc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhoon Yoo</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changhoon Yoo, MD</last_name>
      <phone>+8230101727</phone>
      <email>cyoo.amc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Changhoon Yoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Gastrointestinal Pathology Study Group of Korean Society of Pathologists, Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM, Kim WH, Kim H, Kook MC, Park DY, Lee JH, Chang H, Jung ES, Kim HK, Jin SY, Choi JH, Gu MJ, Kim S, Kang MS, Cho CH, Park MI, Kang YK, Kim YW, Yoon SO, Bae HI, Joo M, Moon WS, Kang DY, Chang SJ. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res Treat. 2012 Sep;44(3):157-65. doi: 10.4143/crt.2012.44.3.157. Epub 2012 Sep 30.</citation>
    <PMID>23091441</PMID>
  </reference>
  <reference>
    <citation>Kim SJ, Kim JW, Oh DY, Han SW, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung). Am J Clin Oncol. 2012 Dec;35(6):549-56. doi: 10.1097/COC.0b013e31821dee0f.</citation>
    <PMID>21659833</PMID>
  </reference>
  <reference>
    <citation>Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172-85. doi: 10.1159/000443167. Epub 2016 Jan 5.</citation>
    <PMID>26731013</PMID>
  </reference>
  <reference>
    <citation>Kang J, Yoo C, Hwang HS, Hong SM, Kim KP, Kim SY, Hong YS, Kim TW, Ryoo BY. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis. Invest New Drugs. 2019 Aug;37(4):763-770. doi: 10.1007/s10637-018-0710-x. Epub 2018 Dec 10.</citation>
    <PMID>30536151</PMID>
  </reference>
  <reference>
    <citation>Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158.</citation>
    <PMID>25014687</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Changhoon Yoo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Neuroendocrine tumor</keyword>
  <keyword>Somatostatin analogue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

